The most important factors for patients seeking health care are quality, access, cost and choice. Here in Minnesota we enjoy some of the highest-quality care in the world. Unfortunately, health care costs continue to increase at an unsustainable rate, and proposals being floated by some in Congress to move to a "Medicare for All" system would have serious impacts on health care access and consumer choice.
Government programs like Medicare control costs in several ways: by limiting the types of care patients receive, reducing consumer choice or underpaying doctors, clinics and hospitals for their costs, which can have the unintended consequence of reducing access. This is especially problematic in rural areas where providers are already struggling to keep their doors open due to an overabundance of patients on Medicare or Medicaid, both of which vastly underpay providers compared to private insurance.
As someone who works with a network of dozens of clinics and hundreds of physicians throughout Minnesota providing individualized care to patients statewide, I can tell you that a one-size-fits-all approach to health care would move us in the wrong direction. The future of health care will be customized and tailored to individual patients. New innovations are helping to reduce redundant testing, minimize readmission and reduce costs systemwide.
Instead of looking for ways to centralize health care that would reduce choice and access, Congress should be embracing the future of individualized medicine by empowering patients with more options and incentivizing providers to compete to deliver high-quality, affordable care.
Tom Lorentzen, Bloomington
The writer is CEO of the Minnesota Healthcare Network.
• • •
The lead editorial on insulin cost reform ("Colorado's smart insulin cost reform," June 5) urged that policymakers should look to Colorado "for inspiration." Later in the piece, it is stated that "there's a cost shift," but there is no recognition that, in fact, Colorado's reform does not address the outrageous cost of the drug, or, more important, that cost's underlying causes.
While this increase in the price charged for insulin is not as flagrant or egregious as was that instituted by former Turing Pharmaceuticals CEO Martin Shkreli, who raised the price of an antiparasitic and antimalarial drug by a factor of 56, it almost certainly has the same root causes: greed and a regulatory environment that encourages this kind of behavior.
Until the fundamental problems in our health care non-system are addressed effectively, the cost-shifting approach should be seen as what it is — a Band-Aid, not a cure. Until efforts are made to align the purposes and motives of all institutions and policymakers in health care to the same goal — the health of all of us — this kind of measure will be only partly successful.